Sanofi (SNYNF) Other Accumulated Expenses (2009 - 2021)
Sanofi (SNYNF) posted Other Accumulated Expenses of $220.4 million for Q4 2021, up 4.87% sequentially from $210.2 million in Q4 2020, and up 4.87% YoY from $210.2 million in Q4 2020.
Sanofi (SNYNF) Other Accumulated Expenses (2009 - 2021) Analysis & Trends
Sanofi (SNYNF) has 13 years of Other Accumulated Expenses data on file, last reported at $220.4 million in Q4 2021.
- Quarterly Other Accumulated Expenses rose 4.87% year-over-year to $220.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $220.4 million (up 4.87% YoY) and the FY2021 annual result came in at $228.0 million, up 13.29% from the prior year.
- Other Accumulated Expenses grew to $220.4 million in Q4 2021 per SNYNF's latest filing, from $210.2 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $10.8 billion in Q4 2017, with the low at $161.3 million in Q4 2019.
- Average Other Accumulated Expenses over 5 years is $4.6 billion, with a median of $220.4 million recorded in 2021.
- Year-over-year, Other Accumulated Expenses jumped 1984.99% in 2017 and plunged 98.13% in 2018.
- Sanofi's Other Accumulated Expenses stood at $10.8 billion in 2017, then slumped by 98.24% to $191.0 million in 2018, then slipped by 15.54% to $161.3 million in 2019, then surged by 30.34% to $210.2 million in 2020, then gained by 4.87% to $220.4 million in 2021.
- Business Quant data shows SNYNF's Other Accumulated Expenses at $220.4 million in Q4 2021, $210.2 million in Q4 2020, and $161.3 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 220.44 Mn |
| Dec 31, 2020 | 210.20 Mn |
| Dec 31, 2019 | 161.27 Mn |
| Jun 30, 2018 | 190.95 Mn |
| Mar 31, 2018 | 10.23 Bn |
| Dec 31, 2017 | 10.85 Bn |
| Jun 30, 2017 | 10.20 Bn |
| Dec 31, 2016 | 472.92 Mn |
| Jun 30, 2016 | 489.24 Mn |
| Dec 31, 2015 | 472.43 Mn |
| Jun 30, 2015 | 9.09 Bn |
| Dec 31, 2014 | 9.64 Bn |
| Jun 30, 2014 | 8.48 Bn |
| Dec 31, 2013 | 9.15 Bn |
| Jun 30, 2013 | 8.20 Bn |
| Dec 31, 2012 | 8.73 Bn |
| Jun 30, 2012 | 8.65 Bn |
| Dec 31, 2011 | 9.73 Bn |
| Jun 30, 2011 | 8.58 Bn |
| Dec 31, 2010 | 381.59 Mn |